BR112012031226A2 - composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica - Google Patents
composto, uso do composto, composição farmacêutica, e uso de composição farmacêuticaInfo
- Publication number
- BR112012031226A2 BR112012031226A2 BR112012031226A BR112012031226A BR112012031226A2 BR 112012031226 A2 BR112012031226 A2 BR 112012031226A2 BR 112012031226 A BR112012031226 A BR 112012031226A BR 112012031226 A BR112012031226 A BR 112012031226A BR 112012031226 A2 BR112012031226 A2 BR 112012031226A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutical
- compound use
- composition use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1009731.9A GB201009731D0 (en) | 2010-06-10 | 2010-06-10 | Kinase inhibitors |
| PCT/GB2011/051076 WO2011154738A1 (en) | 2010-06-10 | 2011-06-09 | Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012031226A2 true BR112012031226A2 (pt) | 2018-03-06 |
Family
ID=42471455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012031226A BR112012031226A2 (pt) | 2010-06-10 | 2011-06-09 | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8916708B2 (pt) |
| EP (1) | EP2580212B1 (pt) |
| JP (1) | JP5791708B2 (pt) |
| KR (1) | KR20130086944A (pt) |
| CN (1) | CN103140489B (pt) |
| AU (1) | AU2011263492B2 (pt) |
| BR (1) | BR112012031226A2 (pt) |
| CA (1) | CA2802010A1 (pt) |
| GB (1) | GB201009731D0 (pt) |
| IL (1) | IL223463A (pt) |
| MX (1) | MX2012014371A (pt) |
| MY (1) | MY159239A (pt) |
| RU (1) | RU2586223C2 (pt) |
| SG (1) | SG186228A1 (pt) |
| UA (1) | UA104677C2 (pt) |
| WO (1) | WO2011154738A1 (pt) |
| ZA (1) | ZA201209289B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140103925A (ko) * | 2011-12-09 | 2014-08-27 | 키에시 파르마슈티시 엣스. 피. 에이. | 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도 |
| DK2788349T3 (en) | 2011-12-09 | 2017-01-30 | Chiesi Farm Spa | kinase inhibitors |
| SG11201402986RA (en) * | 2011-12-09 | 2014-12-30 | Chiesi Farma Spa | Kinase inhibitors |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| MX363950B (es) | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Derivados de urea utiles como inhibidores de quinasa. |
| KR20160015221A (ko) * | 2013-06-06 | 2016-02-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
| CN105377847A (zh) * | 2013-06-06 | 2016-03-02 | 奇斯药制品公司 | 激酶抑制剂 |
| BR112015029504A2 (pt) * | 2013-06-06 | 2017-07-25 | Chiesi Farm Spa | inibidores quinase |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| US11064699B2 (en) | 2017-04-27 | 2021-07-20 | Nihon Nohyaku Co., Ltd. | Condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide |
| US10364245B2 (en) * | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| EP4219489A3 (en) | 2018-05-30 | 2023-11-15 | Washington University | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof |
| US11475172B2 (en) | 2019-03-15 | 2022-10-18 | International Business Machines Corporation | Adjustable viewing angle for a computer privacy filter |
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| CA2389360C (en) * | 1999-11-16 | 2008-06-03 | Steffen Breitfelder | Urea derivatives as anti-inflammatory agents |
| EP1316542A4 (en) | 2000-09-06 | 2005-10-26 | Daicel Chem | 3-AMINO1-INDANOL, METHOD FOR THE PREPARATION AND METHOD FOR OPTICAL RESOLUTION |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| JP2004530690A (ja) * | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| JP4424983B2 (ja) * | 2001-06-05 | 2010-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | １，４−ジ置換ベンゾ−縮合シクロアルキルウレア化合物 |
| EP1458682B1 (en) | 2001-12-20 | 2006-08-30 | Bayer HealthCare AG | 1,4-dihydro-1,4-diphenylpyridine derivatives |
| WO2004072072A1 (en) * | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| EP1716121A1 (en) * | 2003-12-18 | 2006-11-02 | Boehringer Ingelheim Pharmaceuticals Inc. | Polymorph of birb 796, a p38map kinase inhibitor |
| EP1609789A1 (en) | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
| ES2308523T3 (es) | 2004-06-23 | 2008-12-01 | Eli Lilly And Company | Inhibidores de quinasa. |
| GB0418015D0 (en) | 2004-08-12 | 2004-09-15 | Pfizer Ltd | New compounds |
| EP1781655A2 (en) | 2004-08-18 | 2007-05-09 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds useful for the treatment of inflammation |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| CA2620254A1 (en) * | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | P38 map kinase inhibitors and methods for using the same |
| CA2642209A1 (en) * | 2006-02-09 | 2007-08-16 | Pfizer Limited | Triazolopyridine compounds |
| AR063141A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| CA2746357A1 (en) * | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| WO2010094956A1 (en) | 2009-02-17 | 2010-08-26 | Pulmagen Therapeutics (Inflammation) Limited. | Triazolopyridine derivatives as p38 map kinase inhibitors |
| GB201005589D0 (en) * | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
-
2010
- 2010-06-10 GB GBGB1009731.9A patent/GB201009731D0/en not_active Ceased
-
2011
- 2011-06-09 CA CA2802010A patent/CA2802010A1/en not_active Abandoned
- 2011-06-09 MY MYPI2012005302A patent/MY159239A/en unknown
- 2011-06-09 MX MX2012014371A patent/MX2012014371A/es unknown
- 2011-06-09 WO PCT/GB2011/051076 patent/WO2011154738A1/en active Application Filing
- 2011-06-09 JP JP2013513759A patent/JP5791708B2/ja not_active Expired - Fee Related
- 2011-06-09 EP EP11729655.8A patent/EP2580212B1/en active Active
- 2011-06-09 SG SG2012090239A patent/SG186228A1/en unknown
- 2011-06-09 BR BR112012031226A patent/BR112012031226A2/pt not_active IP Right Cessation
- 2011-06-09 CN CN201180026836.3A patent/CN103140489B/zh not_active Expired - Fee Related
- 2011-06-09 RU RU2012153164/04A patent/RU2586223C2/ru not_active IP Right Cessation
- 2011-06-09 AU AU2011263492A patent/AU2011263492B2/en not_active Ceased
- 2011-06-09 UA UAA201213918A patent/UA104677C2/ru unknown
- 2011-06-09 KR KR1020127031394A patent/KR20130086944A/ko active IP Right Grant
- 2011-06-09 US US13/701,989 patent/US8916708B2/en not_active Expired - Fee Related
-
2012
- 2012-12-06 IL IL223463A patent/IL223463A/en active IP Right Grant
- 2012-12-07 ZA ZA2012/09289A patent/ZA201209289B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG186228A1 (en) | 2013-01-30 |
| US8916708B2 (en) | 2014-12-23 |
| JP2013528205A (ja) | 2013-07-08 |
| MX2012014371A (es) | 2013-01-29 |
| EP2580212A1 (en) | 2013-04-17 |
| WO2011154738A1 (en) | 2011-12-15 |
| CA2802010A1 (en) | 2011-12-15 |
| RU2012153164A (ru) | 2014-06-20 |
| KR20130086944A (ko) | 2013-08-05 |
| AU2011263492A1 (en) | 2013-01-10 |
| CN103140489B (zh) | 2016-05-18 |
| EP2580212B1 (en) | 2015-01-28 |
| GB201009731D0 (en) | 2010-07-21 |
| AU2011263492B2 (en) | 2015-11-12 |
| US20130143914A1 (en) | 2013-06-06 |
| JP5791708B2 (ja) | 2015-10-07 |
| ZA201209289B (en) | 2014-02-26 |
| RU2586223C2 (ru) | 2016-06-10 |
| MY159239A (en) | 2016-12-30 |
| CN103140489A (zh) | 2013-06-05 |
| IL223463A (en) | 2016-12-29 |
| UA104677C2 (ru) | 2014-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BRPI1008793A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| BRPI1016219A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112013030302A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo | |
| BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| BR112014029642A2 (pt) | composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112014013178A2 (pt) | composto, composição farmacêutica e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |